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Chronic cigarette smoking and polymorphisms in brain-derived neurotrophic factor (BDNF)
and catechol-O-methyltransferase (COMT) are associated with neurocognition in normal
controls and those with various neuropsychiatric conditions. The influence of BDNF and
COMT on neurocognition in alcohol dependence is unclear. The primary goal of this report
was to investigate the associations of single nucleotide polymorphisms (SNPs) in BDNF
Val66Met (rs6265) and COMT Val158Met (rs4680) with neurocognition in a treatment-
seeking alcohol dependent cohort and determine if neurocognitive differences between
non-smokers and smokers previously observed in this cohort persist when controlled for
these functional SNPs. Genotyping was conducted on 70 primarily male treatment-seeking
alcohol dependent participants (ALC) who completed a comprehensive neuropsychological
battery after 33±9 days of monitored abstinence. After controlling for COMT and BDNF
genotypes, smoking ALC performed significantly worse than non-smoking ALC on the
domains of auditory-verbal and visuospatial learning and memory, cognitive efficiency, gen-
eral intelligence, processing speed, and global neurocognition. In smoking ALC, greater
number of years of smoking over lifetime was related to poorer performance on multi-
ple domains after controlling for genotypes and alcohol consumption. In addition, COMT
Met homozygotes were superior to Val homozygotes on measures of executive skills
and showed trends for higher general intelligence and visuospatial skills, while COMT
Val/Met heterozygotes showed significantly better general intelligence than Val homozy-
gotes. COMT Val homozygotes performed better than heterozygotes on auditory-verbal
memory. BDNF genotype was not related to any neurocognitive domain. The findings
are consistent with studies in normal controls and neuropsychiatric cohorts that reported
COMT Met carriers demonstrated better performance on measures of executive skills
and general intelligence. Results also indicated that the poorer performance of smoking
compared to non-smoking ALC across multiple neurocognitive domains was not mediated
by COMT or BDNF genotype. Overall, the findings lend support to the expanding clinical
movement to make smoking cessation programs available to smokers at the inception of
treatment for alcohol/substance use disorders.
Keywords: cigarette smoking, brain-derived neurotrophic factor, catechol-O-methyltransferase, neurocognition,
alcohol dependence
INTRODUCTION
A number of premorbid and/or comorbid factors may contribute
to the pattern and magnitude of neurocognitive abnormalities
demonstrated by those with alcohol use disorders (AUD; Par-
sons and Nixon, 1993; Oscar-Berman, 2000; Sher et al., 2005;
Rourke and Loberg, 2009). In our previous work assessing the neu-
rocognitive consequences of AUD, we investigated the influence
of chronic cigarette smoking, sociodemographic factors, alcohol
consumption levels, as well as comorbid substance abuse, psy-
chiatric and medical conditions (Durazzo et al., 2006, 2007b,c,
2008, 2010a). Among these variables, chronic cigarette smok-
ing was the sole factor that consistently and robustly predicted
neurocognition in our AUD participants. Specifically, chronic
smoking was associated with significantly poorer performance
on measures of executive skills, processing speed, and learning
and memory. Additionally, longer duration of smoking over life-
time in these studies was consistently related to poorer perfor-
mance on multiple domains of neurocognition after controlling
for age, alcohol consumption, and other potentially mediating
variables.
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Human neurocognition is a complex phenotype that is a func-
tion of psychosocial, environmental, biological, and genetic fac-
tors. With respect to genetic factors, multiple studies have reported
that the Val66Met single nucleotide polymorphism (SNP) of
the brain-derived neurotrophic factor (BDNF; rs6265) and the
Val158Met SNP of the catechol-O-methyltransferase (COMT;
rs4680) genes are associated with several domains of neurocogni-
tive functioning. Specifically, studies have reported that the BDNF
Met allele carriers (i.e., Val/Met, Met/Met) of the BDNF demon-
strated poorer verbal memory (Egan et al., 2003; Hariri et al., 2003;
Dempster et al., 2005; Tan et al., 2005; Schofield et al., 2009), pro-
cessing speed (Miyajima et al., 2008; Raz et al., 2009), and general
intelligence (Tsai et al., 2004; Miyajima et al., 2008) in controls
and individuals with various neuropsychiatric conditions (e.g.,
schizophrenia). The observed relationships between BDNF geno-
types and neurocognition, however, were not uniform across all
studies (Harris et al., 2006; Savitz et al., 2006). For COMT, stud-
ies with controls and individuals with various neuropsychiatric
conditions reported that Met homozygosity was related to better
performance on measures of executive skills, working memory,
and general intellectual functioning. Alternately, several studies
found no relationship between COMT genotype and neurocog-
nition and some reported Val homozygosity was associated with
better neurocognitive performance (for review see Savitz et al.,
2006; Barnett et al., 2008; Dickinson and Elvevag, 2009; Enoch
et al., 2009; Wishart et al., 2011). While the cumulative body of
research appears to suggest COMT Met homozygosity is gener-
ally associated with better performance on working memory and
executive function tasks, the influence of the COMT Val158Met
polymorphism on neurocognition has yet to be fully elucidated
(Barnett et al., 2008; Goldman et al., 2009). Overall, the majority
of research on BDNF has focused on memory function and for
COMT on measures of executive skills and working memory in
healthy controls and individuals with neuropsychiatric disorders
(e.g., schizophrenia-spectrum and bipolar disorders). We are not
aware of any study that specifically investigated the association of
BDNF and COMT polymorphisms with neurocognition in AUD.
Therefore, it is unclear to what extent polymorphisms in BDNF
and COMT are related to neurocognitive function in AUD.
The primary goal of this report was to investigate the associ-
ations of SNPs in BDNF Val66Met (rs6265), COMT Val158Met
(rs4680) with neurocognition in our treatment-seeking alcohol
dependent participants and determine if neurocognitive differ-
ences between non-smokers and smokers previously observed in
this cohort persist when controlled for these functional SNPs.
We predicted that smoking alcohol dependent participants com-
pared to non-smokers perform significantly worse on the domains
of executive skills, processing speed, and learning and memory
after controlling for BDNF and COMT genotypes, alcohol con-
sumption, age, and predicted premorbid intelligence. We also
hypothesized that the inverse relationships between lifetime years
of smoking and neurocognitive performance we observed in our
previous studies are independent of the effects BDNF and COMT
polymorphisms in the current study cohort. Finally, we predicted
that BDNF Val homozygotes perform significantly better than
Val/Met heterozygotes and COMT Met homozygotes show bet-
ter performance than Val homozygotes on measures of executive
skills, learning, memory, and processing speed, after control-
ling for smoking status, alcohol consumption, age, and predicted
premorbid intelligence.
MATERIALS AND METHODS
PARTICIPANTS
Individuals seeking treatment for AUD (n= 70; four females) were
recruited from the VA Medical Center Substance Abuse Day Hos-
pital and the Kaiser Permanente Chemical Dependence Recovery
Program outpatient clinics in San Francisco. All participants pro-
vided written informed consent prior to study according to the
Declaration of Helsinki, and the informed consent document and
procedures were approved by the University of California San
Francisco and the San Francisco VA Medical Center. Participants
were between the ages of 28 and 68 at the time of study and all
met DSM-IV criteria for alcohol dependence (95% with physio-
logical dependence). The alcohol dependent participants (ALC)
completed a comprehensive neuropsychological assessment bat-
tery after 33± 9 days of monitored abstinence. Smoking (n= 39)
and non-smoking (n= 31) ALC did not differ in the duration
of abstinence prior to assessment. All smoking ALC were actively
smoking at the time of assessment and no participant changed
their cigarette consumption from the onset of abstinence to the
time of assessment. Five non-smoking ALC reported a previous
history of chronic smoking, with four quitting more than 8 years
and one more than 3 years prior to enrollment. The performance
of the former smokers was within±0.5 standard deviations of the
non-smoking ALC group mean across neurocognitive domains.
The vast majority of ALC in this study were participants in our
previous research (Durazzo et al., 2008, 2010a). Demograph-
ics, indices of alcohol consumption, smoking severity, depressive
and anxiety symptomatology, and frequency of medical, psy-
chiatric, and substance use comorbidities for ALC are given in
Table 1.
Primary inclusion criteria were current DSM-IV diagnosis of
alcohol dependence or abuse, fluency in English, consumption
of greater than 150 alcoholic drinks per month (one alcoholic
drink equivalent= 13.6 g pure ethanol) for at least 8 years prior to
enrollment for men, and consumption of greater than 80 drinks
per month for at least 8 years prior to enrollment for women. Pri-
mary exclusion criteria are fully detailed in our previous work
(Durazzo et al., 2004). In summary, no participant had a his-
tory of a neurologic (e.g., non-alcohol-related seizure disorder,
neurodegenerative disorder, demyelinating disorder; traumatic
brain injury with loss of consciousness >15 min), general med-
ical (e.g., myocardial infarction, Type-1 diabetes, cerebrovascular
accident), or psychiatric (e.g., schizophrenia-spectrum, bipolar
disorder, post-traumatic stress disorder, substance dependence
within 5 years prior to study) conditions known or suspected to
influence neurocognition. The following comorbidities were per-
mitted due to their high prevalence in AUD (Gilman and Abraham,
2001; Stinson et al., 2005): hepatitis C, type-2 diabetes, hyperten-
sion, unipolar mood (major depression, substance-induced mood
disorder), and anxiety (generalized anxiety disorder, panic disor-
der). ALC who met DSM-IV criteria for current or past substance
abuse were included. Current opioid replacement therapy (e.g.,
methadone) was exclusionary.
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Table 1 | Participant demographics and clinical measures.
Measure ALC (n=70)
Age 51.0±10.0
Education 14.0±2.2
Days abstinent 33±9
AMNART 114±9
1-year average drinks/month 398±206
8-year average drinks/month 314±163
Lifetime average drinks/month 208±100
Months of heavy drinking 259±116
Age onset heavy drinking 26±10
FTND 5.5±2.7
Cigarette pack years 25±18
Lifetime years of smoking 25±12
Beck Depression Inventory 11.1±9.0
STAI-trait 43.1±11.0
% smokers 56
% with psychiatric comorbidity 44
% with substance comorbidity 24
% with medical comorbidity 44
GGT 44±25
Prealbumin 27±6
AMNART, American National Adult ReadingTest; FTND, FagerstromTest for Nico-
tine Dependence; GGT, gamma glutamyltransferase, normal range 7–64; insti-
tutional units; prealbumin (proxy measure of nutritional status), normal range
18–45 mg/dl; STAI, State-Trait Anxiety Inventory; (mean±SD).
MEDICAL, PSYCHIATRIC, SUBSTANCE, AND DRINKING HISTORY
ASSESSMENT
Participant medical history was obtained from self-report and
confirmed via available medical records. Participants completed
the Structured Clinical Interview for DSM-IV Axis I disorders,
Patient Edition,Version 2.0 (SCID-I/P; First et al., 1998), and stan-
dardized questionnaires assessing lifetime alcohol consumption
(Lifetime Drinking History, LDH; Skinner and Sheu, 1982; Sobell
et al., 1988) and substance use (in-house questionnaire assess-
ing substance type, and quantity and frequency of use). From the
LDH we derived average number of alcohol-containing drinks per
month over 1 and 8 years prior to enrollment, average number
of drinks per month over lifetime, number of lifetime years of
regular drinking (i.e., consuming at least one alcoholic drink per
month), number of months of heavy drinking (i.e., total num-
ber of months over lifetime of drinking in excess of 100 drinks
per month), age of onset of heavy drinking and total kilograms
of ethanol consumed over lifetime. Participants completed self-
report measures of depressive (Beck Depression Inventory, BDI;
Beck, 1978) and anxiety symptomatology (State-Trait Anxiety
Inventory, form Y-2, STAI; Spielberger et al., 1977), and nicotine
dependence [Fagerstrom Tolerance Test for Nicotine Dependency
(FTND; Fagerstrom et al., 1991)]. The total number of cigarettes
currently smoked per day, number of years of smoking at the cur-
rent level and over lifetime were also recorded, and pack years [i.e.,
(number of cigarettes per day/20)× lifetime number of years of
smoking] calculated for smoking ALC.
NEUROPSYCHOLOGICAL ASSESSMENT
Participants completed a comprehensive battery, which evaluated
domains of neurocognitive function previously reported to be
affected by AUD (Oscar-Berman, 2000; Rourke and Loberg, 2009)
and chronic cigarette smoking (Durazzo et al., 2007a; Swan and
Lessov-Schlaggar, 2007). Smoking ALC were allowed to smoke
ad libitum prior to assessment and to take smoking breaks dur-
ing testing if requested. The neurocognitive domains evaluated
and the constituent measures were as follows: Executive skills:
Short Categories Test (Wetzel and Boll, 1987), color-word por-
tion of the Stroop Test (Golden, 1978), Trail Making Test part
B (Reitan and Wolfson, 1985), Wechsler Adult Intelligence Scale
3rd Edition (WAIS-III) Similarities (Wechsler, 1997), Wiscon-
sin Card Sorting Test-64: Computer Version 2-Research Edition
(Kongs et al., 2000) non-perseverative errors, perseverative errors,
and perseverative responses General intelligence: Ward-7 Full Scale
IQ (Axelrod et al., 2001; based on WAIS-III Arithmetic, Block
Design, Digit Span, Digit Symbol, Information, Picture Comple-
tion, and Similarities subtests; Wechsler, 1997). Learning and mem-
ory : Auditory-verbal: California Verbal Learning Test-II (Delis
et al., 2000), Immediate Recall trials 1–5 (learning), Short and
Long Delay Free Recall (memory). Visuospatial: Brief Visuospatial
Memory Test-Revised (Benedict, 1997), Total Recall (learning),
and Delayed Recall (memory). Processing speed : WAIS-III Digit
Symbol, Stroop Color and Word (Golden, 1978), WAIS-III Sym-
bol Search (Wechsler, 1997), Trail Making Test-A (Reitan and
Wolfson, 1985). Visuospatial skills: WAIS-III Block Design; Luria–
Nebraska Item 99 (Golden et al., 1978). Working memory :WAIS-III
Arithmetic, WAIS-III Digit Span. Cognitive efficiency : this domain
consisted of all tests that were timed, or in which the time to
complete the task influenced the score achieved, and was cal-
culated by averaging the individual z-scores of those measures
(see below). Timed tests included the Luria–Nebraska Item 99
ratio, Stroop word, color, and color-word tests, Trails A and B
and WAIS-III Arithmetic, Block Design, Digit Symbol, Picture
Completion, and Symbol Search. Higher scores on these mea-
sures reflect better speed and accuracy on principally non-verbal
tasks. The cognitive efficiency domain is an approximation of the
concept of cognitive efficiency previously described by Glenn and
Parsons (1992) and Nixon et al. (1995, 1998). Premorbid verbal
intelligence was estimated with the American National Adult Read-
ing Test (Grober and Sliwinski, 1991). For the Luria–Nebraska
Item 99, the number correct (maximum possible= 8) was divided
by the time required to complete the task. This ratio was used
due to the low ceiling for the number of correct responses (i.e.,
most participants achieved a score of 6 or better), which resulted
in a highly skewed and non-Gaussian distribution. The ratio of
number correct to time to complete the Luria 99 was normally
distributed.
Raw scores for all neurocognitive measures, except the Luria–
Nebraska Item 99 ratio, were converted to age-adjusted stan-
dardized scores via the normative data accompanying the par-
ticular measure (i.e., BVMT-R, CVLT-II, Short Categories Test,
Stroop Color-Word Test, WAIS-III subtests) or age and education
[(WCST-64 variables; Trails A and B via Heaton Compendium
Norms (Heaton et al., 1991)]. Standardized scores were trans-
formed to z-scores for all measures. For the Luria–Nebraska Item
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99 ratio, raw scores were converted to z-scores based on the per-
formance of 32 non-smoking light drinking controls, as there are
no published norms available for this measure. A global neurocog-
nitive functioning score was calculated from the arithmetic mean
of z-scores for all of the individual domains.
GENOTYPING
Genomic DNA was isolated from whole blood. The SNPs were
assayed using TaqMan genotyping assays from Applied Biosystems,
Foster City, CA, USA. SNP assays were performed using a reaction
volume of 15µl, which consisted of 7.5µl of TaqMan 2X universal
master mix, 0.38µl of 20X TaqMan pre-designed SNP genotyp-
ing assay, 6.14µl of nuclease-free water, and 1µl genomic DNA.
After PCR amplification as per manufacturer’s recommendations,
SNP genotypes were determined by allelic discrimination using
the ABI-7500 instrument. BDNF (χ2= 0.79, p= 0.37) and COMT
(χ2= 0.01, p= 0.92) were in Hardy–Weinberg equilibrium (see
Table 2).
DATA ANALYSES
Multivariate analyses of covariance (MANCOVA) examined
effects of BDNF and COMT genotypes and smoking status on the
11 domains of neurocognition (see Table 3 for list of domains),
with age, AMNART, and lifetime average drinks per month as pri-
mary covariates. In our previous work with this alcohol dependent
cohort, age accounted for a significant amount of the variance in
neurocognition despite the use of age-corrected norms (Durazzo
et al., 2008, 2010a); therefore, age was also used as a covariate in
this study. Significant MANCOVA omnibus effects (p= 0.05) for
genotypes and smoking status were followed-up with pairwise t -
tests. To control for the potential influence of medical (primarily
hypertension and positivity for the hepatitis C antibody), psychi-
atric (primarily unipolar mood disorders), and substance abuse
history on neurocognition, pairwise comparisons achieving statis-
tical significance were reanalyzed using medical, psychiatric, and
substance use comorbidities, individually, as additional covariates.
Significance levels of all pairwise comparisons were adjusted for
multiplicity of tests. Alpha levels (p= 0.05) for pairwise compar-
isons for BDNF and COMT genotypes and smoking status were
adjusted for the number of neurocognitive domains evaluated
(i.e., 11) and the average intercorrelation among the domains (i.e.,
r = 0.55), resulting in a corrected p-values of 0.017 (see Sankoh
et al., 1997). Effect sizes (ES) for pairwise comparisons were
Table 2 | Genotype frequency for BDNFVal66Met, COMTVal158Met.
SNP Genotype Frequency Percent
BDNF (rs6265) Val/Val 47 67.1
Val/Met 22 31.4
Met/Met 1 1.5
COMT (rs4680) Val/Val 21 30.0
Val/Met 35 50.0
Met/Met 14 20.0
SNP, single nucleotide polymorphism. All genotypes were in Hardy–Weinberg
equilibrium (χ2 <0.83, p>0.36).
calculated via Cohen’s d (Cohen, 1988). For smoking ALC, associ-
ations (i.e., semi-partial correlations) between the 11 neurocog-
nitive domains, genotypes, lifetime average drinks per month,
and lifetime years of smoking were examined with multiple linear
regression (all predictors simultaneously entered into the model).
Analyses were completed with SPSS v18.0.
RESULTS
PARTICIPANT CHARACTERIZATION
Participants were 51.0± 10.0 years of age, had 14.0± 2.2 years of
formal education and were abstinent for 33± 9 days at the time
of study. Eighty percent of ALC participants were Caucasian, 13%
African American, 4% Latino, 2% Native American, and 1% Pacific
Islander. See Table 1 for additional demographics and clinical
measures.
SMOKING STATUS, COMT AND BDNF GENOTYPES, AND
NEUROCOGNITIVE FUNCTION
Multivariate analyses of covariance indicated significant omnibus
effects for smoking status [F (10, 53)= 3.18, p< 0.003], COMT
genotype [F (20, 108)= 1.77, p= 0.042], age [F (10, 53)= 2.97,
p= 0.005], and AMNART [F (10, 53)= 11.74, p< 0.001]. BDNF
genotype and lifetime average drinks per month were not signif-
icant predictors of neurocognition. Inspection of pairwise tests
across domains for BDNF Val homozygotes versus heterozygotes
revealed all comparisons were p> 0.15, with trivial ES (all<0.16).
Pairwise comparisons indicated smoking ALC performed
worse than non-smoking ALC on the following domains of
functioning: auditory-verbal learning (p< 0.001; ES= 0.83),
auditory-verbal memory (p< 0.001; ES= 0.87), cognitive effi-
ciency (p< 0.001; ES= 0.97), general intelligence (p< 0.001;
ES= 0.92), processing speed (p< 0.001; ES= 0.97), visuospatial
learning (p= 0.001; ES= 0.75), visuospatial memory (p= 0.007;
ES= 0.60), and global neurocognition (p< 0.001; ES= 1.09).
Smoking ALC showed a trend for lower executive skills (p= 0.05;
Table 3 | Associations between neurocognitive domains
(age-corrected) and lifetime years of smoking for smoking ALC
(n=39).
Neurocognitive domain Lifetime years of smoking
Auditory-verbal learning −0.39**
Auditory-verbal memory −0.38*
Cognitive efficiency −0.37**
Executive skills −0.23
General intelligence −0.27*
Processing speed −0.30*
Visuospatial learning −0.50**
Visuospatial memory −0.45**
Visuospatial skills −0.43**
Working memory −0.16
Global neurocognition −0.49**
*p<0.05; **p<0.01; all tests two-tailed. Correlations are semi-partial coeffi-
cients controlling for AMNART, lifetime average drinks per month, BDNF, and
COMT genotypes.
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ES= 0.40). Controlling the above listed pairwise tests for COMT,
medical, psychiatric, and substance abuse comorbidities did not
appreciably alter the above p-values or ES for differences between
smoking and non-smoking ALC.
Pairwise comparisons showed COMT Met homozygotes (i.e.,
Met/Met) were superior to Val homozygotes (i.e.,Val/Val) on exec-
utive skills (p= 0.013, ES= 0.75) and showed trends for higher
general intelligence (p= 0.035, ES= 0.61) and visuospatial skills
(p= 0.022, ES= 0.69) than Val homozygotes. Val/Met heterozy-
gotes demonstrated a significantly better performance on the
general intelligence domain than Val homozygotes (p= 0.014,
ES= 0.45). Val homozygotes performed significantly better than
Val/Met on auditory-verbal memory (p= 0.012, ES= 0.65). Con-
trolling the above listed pairwise tests for smoking status, medical,
psychiatric, and substance abuse comorbidities did not alter the
above reported results.
ASSOCIATIONS OF GENOTYPES WITH ALCOHOL CONSUMPTION AND
LIFETIME YEARS OF SMOKING
No significant associations were observed among BDNF and
COMT genotypes,alcohol consumption measures,and the 11 neu-
rocognitive domains. For smoking ALC, higher lifetime years of
smoking showed moderate to strong inverse relationships with
performance on multiple neurocognitive domains after control-
ling for AMNART, lifetime average drinks per month, BDNF
and COMT genotypes (see Table 3). There were no relationships
between FTND score (i.e., level of nicotine dependence) and any
neurocognitive domain.
DISCUSSION
The primary findings from this cohort of primarily male,
treatment-seeking alcohol dependent individuals with approxi-
mately 1 month of abstinence from alcohol were as follows: (1)
smoking ALC demonstrated significantly poorer performance
than non-smoking ALC on multiple domains of neurocognition
after controlling for COMT and BDNF genotypes and medical,
psychiatric, and substance abuse comorbidities; (2) in smoking
ALC, greater number of lifetime years of smoking was associated
with worse performance on multiple neurocognitive domains;
(3) COMT genotype was significantly associated with measures
of executive skills, general intelligence, and visuospatial memory;
and (4) the BDNF Val66Met polymorphism was not a significant
predictor of any neurocognitive domain.
Chronic cigarette smoking in this cohort of alcohol dependent
individuals in early recovery was a robust predictor of perfor-
mance in multiple domains of neurocognition after controlling
for BDNF and COMT genotypes, lifetime alcohol consumption,
age, and AMNART. The pattern of inferior performance of smok-
ing ALC relative to non-smoking ALC and the moderate to strong
ES for the group differences are consistent with our previous
research (Durazzo et al., 2008, 2010a) as well as with findings
from other studies (e.g., Glass et al., 2006, 2009). Additionally,
in smoking ALC, the relationships of greater number of years of
lifetime smoking to age-adjusted scores on multiple neurocogni-
tive domains remained significant and robust after controlling for
BDNF and COMT, lifetime alcohol consumption, and comorbid
conditions. Taken together, this suggests that the inferior per-
formance of smoking compared to non-smoking ALC and the
moderate to strong associations of lifetime years of smoking
with neurocognition in smoking ALC were not mediated by the
SNPs investigated, cumulative amount of alcohol consumed over
lifetime, or conditions that are highly comorbid with AUD.
When assessing the effects of chronic cigarette smoking on
neurocognition, it is important to distinguish between the effects
of acute ingestion, metabolism and withdrawal of nicotine, and
the influence of chronic exposure to the multitude of noxious
compounds contained in cigarette smoke. Acute nicotine admin-
istration has been found to transiently improve some areas of neu-
rocognition in healthy non-smokers and individuals with atten-
tion deficit hyperactivity disorder and schizophrenia-spectrum
disorders, predominantly on measures of sustained attention and
working memory (Rezvani and Levin, 2001; Sacco et al., 2004;
Mansvelder et al., 2006). Acute nicotine administration in nico-
tine deprived smokers is associated with improved cognitive task
performance (Mendrek et al., 2006; Parrott, 2006), whereas several
studies report decrements in neurocognitive performance with
nicotine administration to non-smokers (see Mansvelder et al.,
2006 for review). A recent meta-analysis conducted by Heishman
et al. (2010) suggests that acute smoking or nicotine consumption,
independent of withdrawal effects, are associated with enhanced
performance in the following domains of function: fine motor
skills, alerting attention accuracy and response time, orienting
attention reaction time, short-term episodic memory accuracy,
and working memory reaction time (but not accuracy). There is
limited placebo controlled research assessing the effects of acute
nicotine administration in AUD. In alcohol dependent smok-
ers with 40± 17 days of abstinence, a high acute nicotine dose
administered via transdermal patch (14 and 21 mg for females
and males, respectively), was related to greater accuracy on a mea-
sure of vigilance and working memory than a low nicotine dose
(7 mg; Boissoneault et al., 2011), but neither the high nor the low
nicotine dose influenced immediate or delayed auditory-verbal
memory performance (Gilbertson et al., 2011). Greater pack years
(a composite measure of smoking intensity and chronicity), was
related to longer reaction times and lower accuracy on the vigilance
and working memory task (Boissoneault et al., 2011). Similarly,
in community-based samples of men with a lifetime history of
alcohol dependence, higher pack years were inversely related to
measures of cognitive proficiency and general intelligence (Glass
et al., 2006) and both smoking and alcoholism severities were
inversely related to executive function (Glass et al., 2009). In this
study, longer lifetime smoking duration was associated with poorer
performance on multiple neurocognitive domains, which is con-
sistent with the findings for pack years in the above studies. sALC
in this study were allowed to smoke ad libitum prior to assessment
and to take smoke breaks during the assessment. The plasma half-
life of nicotine is about 2 h (Nakajima and Yokoi, 2005), and, with a
2 h half-life, plasma nicotine levels will accrue (e.g., 3 or more half-
lives) with regular smoking during waking hours (Hukkanen et al.,
2005); therefore, nicotine withdrawal likely did not confound any
of our findings (for review see Sacco et al., 2004). Taken together,
acute nicotine administration in smoking AUD may facilitate per-
formance on some aspects of neurocognition; however, it appears
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that increasing smoking intensity and/or chronicity in AUD is
robustly related to poorer performance on multiple neurocogni-
tive functions and may mitigate any enhancing effects of acute
nicotine consumption, particularly with greater levels of smok-
ing severity and/or chronicity. For further discussion of potential
mechanisms associated with the neurocognitive and neurobiolog-
ical effects of chronic cigarette smoking in AUD and non-clinical
samples (see Durazzo and Meyerhoff, 2007; Durazzo et al., 2010b).
The most consistent finding for COMT in this alcohol depen-
dent cohort was that Met allele carriers performed better than
Val homozygotes on measures of executive skills and general
intelligence. Specifically, Met homozygotes and Val/Met heterozy-
gotes performed significantly better than Val homozygotes on
the executive skills and general intelligence domains, respectively.
Met homozygotes showed trends for better performance than Val
homozygotes on the general intelligence and visuospatial skills
domains. Moderate ES were apparent for the differences between
COMT Met carriers and Val homozygotes. There were no signifi-
cant differences between COMT Met homozygotes and Val/Met
heterozygotes, and Val homozygotes were not superior to Met
homozygotes on any neurocognitive domain. Our COMT findings
for the executive skills domain in this alcohol dependent cohort
are consistent with studies of the COMT rs4680 SNP in normal
controls and individuals with neuropsychiatric disorders, which
reported that Met homozygotes were superior to Val homozy-
gotes on measures of executive skills (Savitz et al., 2006; Wishart
et al., 2011). With respect to specific measures of executive skills,
studies have found Met homozygotes made significantly less per-
severative responses or perseverative errors on the WCST than
Val homozygotes across cohorts of normal controls, individu-
als at risk for schizophrenia, and schizophrenics (Joober et al.,
2002; Malhotra et al., 2002; Mattay et al., 2003; Rosa et al., 2004).
COMT Met homozygotes in this report also made less persever-
ative errors and perseverative responses on the WCST than Val
homozygotes (p< 0.05), after controlling for BDNF genotype,
smoking status, lifetime alcohol consumption, age, and AMNART
(data for individual tests not shown). The influence of the COMT
Val158Met SNP on neurocognition may be related to its effects
on the regulation of tonic and phasic dopamine activity (DA)
in the frontal lobe neocortex. The G→A missense mutation in
this SNP translates into a substitution of Val by Met at codon
158. Physiologically, the Val158Met SNP affects the thermostabil-
ity of the COMT enzyme in a Met dose-dependent fashion such
that Met homozygotes demonstrate approximately 50% reduc-
tion in enzymatic activity in the frontal lobe cortex (see Dick-
inson and Elvevag, 2009). The decreased enzymatic activity of
COMT Met allele carriers is thought to result in higher tonic and
more stable DA concentrations at paralimbic and neocortical D1
receptors and lower phasic alterations in subcortical DA levels,
which is suggested to relate to better and more consistent perfor-
mance on abilities subserved by the anterior frontal-subcortical
circuits, particularly executive skills and working memory (see
Bilder et al., 2004; Dickinson and Elvevag, 2009). The superior per-
formance of Met carriers relative to Val homozygotes on measures
of executive and intellectual skills is consistent with the suggested
effects of COMT genotype on tonic-phasic DA neurotransmission
in anterior frontal-subcortical circuits subserving higher order
neurocognitive functions. Contrary to previous studies, the BDNF
Val66Met polymorphism was not a significant predictor of any
neurocognitive domain. ES for pairwise comparisons of BDNF
genotypes across the 11 domains were trivial (0.01–0.15), which
suggests the lack of significant findings in Val homozygotes and
Met Carriers were not a function of insufficient statistical power.
Age was a significant predictor of all domains except of
auditory-verbal learning and memory and working memory,
despite the use of age-adjusted norms. Fast, flexible, and accurate
responses are required for better scores on the predominantly
non-verbal/visuospatial tasks comprising the cognitive efficiency,
processing speed, and visuospatial skills domains, as well as on
WAIS-III non-verbal tasks contributing to the general intelligence
domain. Research on normal age-related changes in neurocogni-
tion suggests decreasing information processing speed is signifi-
cantly related to the declines in learning, memory, and visuospatial
abilities with increasing age (Salthouse, 1996, 2000; Christensen,
2001; Finkel et al., 2007; Kochunov et al., 2010). Overall, the
age effects observed in this study are congruent with the “pre-
mature aging” hypothesis in AUD (Oscar-Berman, 2000). It is
also noteworthy that, in this report, and in our earlier work
(Durazzo et al., 2007c, 2008, 2010a) measures of alcohol consump-
tion were not associated with neurocognition. This is consistent
with other research that found measures of alcohol consumption
quantity/frequency were weakly or not related to neurocognition
(Schafer et al., 1991; Beatty et al., 1995, 2000; Eckardt et al., 1998;
Horner et al., 1999; Sullivan et al., 2000).
This study has limitations that may influence the generaliz-
ability of the findings. The sample size of this study was modest,
which did not permit a full factorial examination of all predic-
tors (e.g., gene× gene interactions) and possibly led to inadequate
power to detect other potential relationships between COMT and
the neurocognitive domains investigated. We did not assess for
personality disorders, which may contribute to the neurocogni-
tive and neurobiological abnormalities observed in AUD (Eckardt
et al., 1995; Kuruoglu et al., 1996; Giancola and Moss, 1998; Costa
et al., 2000). Results may have also been influenced by factors
not directly assessed in this study, such as diet, exercise, and expo-
sure to environmental cigarette smoke or other premorbid/genetic
variables. Finally, the majority of participants were males recruited
from the San Francisco VA Medical Center, which did not allow for
the examination of the potential effects of sex on neurocognition.
In summary, chronic cigarette smoking was strongly related to
poorer performance on multiple neurocognitive domains, while
the COMT Val158Met polymorphism showed significant associa-
tions with three domains (executive skills, general intelligence, and
auditory-verbal memory) in this cohort of short-term abstinent
alcohol dependent individuals. Importantly, our results indicate
that the inferior performance demonstrated by smoking compared
to non-smoking ALC was not mediated by the SNPs investigated,
alcohol consumption, or comorbid medical and psychiatric con-
ditions. The current findings reinforce our previous work that
indicates consideration of smoking status and other prevalent
comorbid conditions in AUD is critical to fully appreciate how this
clinical syndrome influences neurocognition. Our results for the
relationships of COMT polymorphism to neurocognition in AUD
were consistent with findings in normal controls and individuals
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with schizophrenia-spectrum disorders. Research investigating the
influence of BDNF and COMT on neurocognitive recovery during
sustained abstinence from alcohol in this cohort is clearly indi-
cated. Cigarette smoking is a modifiable health risk that is directly
associated with at least 440,000 deaths in the United States alone
and 10 million annual deaths worldwide, with greater mortality
and morbidity among those with substance use disorders, mood
disorders, and schizophrenia (see Durazzo and Meyerhoff, 2007
for review). This study provides clinicians with additional infor-
mation on the adverse consequences of chronic smoking in those
seeking treatment for AUD. In the face of high mortality from ciga-
rette smoking in AUD (Hurt et al., 1996), the data from this report
in conjunction with other neurocognitive and neuroimaging stud-
ies (see Durazzo and Meyerhoff, 2007; Durazzo et al., 2010b), lend
strong support to the expanding clinical movement (which is stan-
dard practice at the San Francisco VA Medical Center) to make
smoking cessation programs available to smokers at the inception
of treatment for alcohol/substance use disorders.
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